About
Aspireo Pharmaceuticals Ltd is a biopharmaceutical company focused on the development of a novel somatostatin analog (SSA) for the treatment of diseases resulting from hormone-active tumors, such as acromegaly, neuroendocrine and gastroenteropancreatic tumors, Cushings disease, and diabetic retinopathy. Aspireos sole development compound is Somatoprim (DG3173), a novel and proprietary somatostatin analog that is based on a novel amino acid composition and an innovative backbone cyclization technology used for stabilization of the peptide. During extensive preclinical testing, Somatoprim has demonstrated a receptor binding and pharmacological profile thatis significantly differentiated from SSAs that are currently marketed or in clinical development. In particular, Somatoprim has demonstrated an improved side effect profile with minimal adverse effects on the gastrointestinal tract and metabolic control. Furthermore, assessment of growth hormone secretion in cultured human somatotroph adenoma tissue treated with Somatoprim suggests that it has the potential to significantly increase the response rate of acromegalic patients to SSA therapy. Aspireos only investor is TVM Capital, a dedicated provider of equity capital to the international pharmaceutical, biopharmaceutical, medical technology, and healthcare diagnostics industries. Aspireo is an Israeli company that was established by TVM Capital as a Project Focused Company (PFC). Aspireo and the Somatoprim project are managed by a team of dedicated and experienced executives that are supported by a group of collaborators and consultants with complementary knowledge and skills.
Q&A
- What is Aspireo Pharmaceuticals' primary focus?
- Aspireo Pharmaceuticals is a biopharmaceutical company focused on developing a novel somatostatin analog (SSA) for treating diseases caused by hormone-active tumors, including acromegaly, neuroendocrine tumors, Cushing's disease, and diabetic retinopathy.
- What is the name of Aspireo Pharmaceuticals' main development compound?
- Aspireo Pharmaceuticals' sole development compound is Somatoprim (DG3173), a proprietary somatostatin analog.
- What differentiates Somatoprim from other somatostatin analogs?
- Somatoprim has demonstrated a differentiated receptor binding and pharmacological profile, with an improved side effect profile showing minimal adverse effects on the gastrointestinal tract and metabolic control during preclinical testing.
- Who is the primary investor in Aspireo Pharmaceuticals?
- Aspireo Pharmaceuticals' only investor is TVM Capital, which specializes in providing equity capital to the international pharmaceutical, biopharmaceutical, medical technology, and healthcare diagnostics industries.
- What is the operational status of Aspireo Pharmaceuticals?
- Aspireo Pharmaceuticals is currently inactive, as of May 2015.
- When was Aspireo Pharmaceuticals founded?
- Aspireo Pharmaceuticals was founded in January 2010.
- How many employees does Aspireo Pharmaceuticals have?
- Aspireo Pharmaceuticals has 1-10 employees.
- What is Aspireo Pharmaceuticals' current funding stage?
- Aspireo Pharmaceuticals is in the Pre-Funding stage.
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/6156145 |
Identifiers & details
| Founded | 2010-1 |
|---|---|
| Status reason | Non Active, May 2015 |